Sustainability Report

Overview

The report covers Pharmesis International Ltd's FY2024 and highlights consolidated revenue of RMB 67.6 million and profit before tax of RMB 8.4 million. It reports zero drug safety incidents and zero workplace injuries in FY2024. The report also describes direct Board oversight of material ESG factors and sustainability governance involving management and the Risk Management Committee.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Publication date: 1 April 2025
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Ratings

GRI level

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services